Failure mode and bimodal restenosis of drug-coated balloon in femoropopliteal intervention

被引:7
|
作者
Huang, Hsuan-Li [1 ,2 ]
Chou, Hsin-Hua [1 ,2 ]
Chen, I-Chih [3 ]
Hsieh, Chien-An [1 ]
Jang, Shih-Jung [1 ]
Tzeng, I-Shiang [4 ]
Ko, Yu-Lin [1 ,2 ]
机构
[1] Buddhist Tzu Chi Med Fdn, Taipei Tzu Chi Hosp, Div Cardiol, Dept Internal Med, New Taipei, Taiwan
[2] Tzu Chi Univ, Sch Med, Hualien, Taiwan
[3] Tainan Municipal Hosp, Div Cardiol, Dept Internal Med, Tainan, Taiwan
[4] Buddhist Tzu Chi Med Fdn, Taipei Tzu Chi Hosp, Dept Res, New Taipei, Taiwan
关键词
Drug-coated balloon; Restenosis; Femoropopliteal; Failure mode; PACLITAXEL-ELUTING STENTS; CLINICAL-OUTCOMES; ARTERY-DISEASE; ZILVER PTX; FEMORAL-ARTERY; CLASSIFICATION; EPIDEMIOLOGY; PREVALENCE; PATTERNS; IMPACT;
D O I
10.1016/j.ijcard.2018.02.040
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Pattern of DCB restenosis and associated outcomes in facing complex femoropopliteal lesions remain uncertain. Methods: Data were retrospectively collected from dual centers in Taiwan on patients who underwent treatment with DCBs for femoropopliteal lesions between 2013 and 2016. The restenosis pattern was categorized by the index-treated length. Clinical outcomes and time to DCB restenosis were retrospectively analyzed. Cox proportional hazards model identified restenosis predictors. Results: We recruited a total of 164 patients (91 men; median age 73 years) into the final analysis. The mean lesion length was 204.0 +/- 109.2 mm. Of them, 45% total occlusions, 28% severe calcification and 15% in-stent restenosis were treated. Fifty-five patients have DCB restenosis (28 focal and 27 diffuse-occlusive patterns) over a 55-month follow-up. The median restenosis time emerged as a bimodal pattern with a significant difference between the diffuse-occlusive and focal restenosis group (225 vs. 484 days, P = 0.01). The 1-year patency rate after reintervention for DCB restenosis also was different between both restenosis group (29% vs. 65%, P = 0.017). The anticipated timing of escape for diffuse-occlusive or focal restenosis was 687 and 1068 days, respectively. Independent factorswere lesion length (P = 0.049) for diffuse-occlusive restenosis and lumen gain of the popliteal artery for focal restenosis (P = 0.034). Conclusions: This study demonstrated time to DCB failure emerged as a bimodal pattern of distribution and associations of restenosis pattern to subsequent outcomes after the repeated intervention. Exemption from late catchup restenosis required 3-year observation instead of the 1-year mark for conventional treatment. (c) 2018 Elsevier B.V. All rights reserved.
引用
收藏
页码:170 / 177
页数:8
相关论文
共 50 条
  • [41] Treatment of femoropopliteal arterial lesions with excimer laser atherectomy and drug-coated balloon
    Liao, Zhijie
    Qin, Jinbao
    Liu, Linbo
    Zhang, Heng
    Tang, Qi
    Liu, Wentao
    Yin, Minyi
    Lu, Xinwu
    Zhang, Yi
    VASCULAR, 2025,
  • [42] Drug-coated vs uncoated balloon angioplasty in the treatment of femoropopliteal arterial lesions
    Eldesouky, Mahmoud S.
    Sharaf, Mohamed M.
    Alkhateep, Yahia M.
    EGYPTIAN JOURNAL OF SURGERY, 2020, 39 (01): : 252 - 260
  • [43] Neutrophil-to-Lymphocyte Ratio Predicts Restenosis After Drug-Coated Balloon Therapy for Femoropopliteal Artery Lesions: A Retrospective Study
    Wang, Zhihong
    Sheng, Lei
    Gu, Hongbin
    Yang, Fan
    Xie, Huajie
    Li, Mingfei
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [44] Femoropopliteal In-Stent Restenosis: Gaining Ground With Excimer Laser and Drug-Coated Balloons
    Shammas, Nicolas W.
    JOURNAL OF ENDOVASCULAR THERAPY, 2018, 25 (01) : 89 - 91
  • [45] Nationwide trends in drug-coated balloon and drug-eluting stent utilization in the femoropopliteal arteries
    Mohapatra, Abhisekh
    Saadeddin, Zein
    Bertges, Daniel J.
    Madigan, Michael C.
    Al-Khoury, Georges E.
    Makaroun, Michel S.
    Eslami, Mohammad H.
    JOURNAL OF VASCULAR SURGERY, 2020, 71 (02) : 560 - 566
  • [46] Nationwide Trends in Drug-Coated Balloon and Drug-Eluting Stent Utilization in the Femoropopliteal Arteries
    Mohapatra, Abhisekh
    Bertges, Daniel J.
    Madigan, Michael C.
    Al-Khoury, Georges E.
    Makaroun, Michel S.
    Eslami, Mohammad H.
    JOURNAL OF VASCULAR SURGERY, 2018, 68 (02) : E15 - E16
  • [47] Plain uncoated balloon versus drug-coated balloon in the management of in-stent restenosis of femoropopliteal lesions: a comparative study of the effect of lesion length on the outcome
    Ismail, Osama
    Radwan, Ahmed
    Elhindawy, Khaled
    EGYPTIAN JOURNAL OF SURGERY, 2022, 41 (01): : 231 - 238
  • [48] The LEVANT I (Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis) Trial for Femoropopliteal Revascularization First-in-Human Randomized Trial of Low-Dose Drug-Coated Balloon Versus Uncoated Balloon Angioplasty
    Scheinert, Dierk
    Scheinert, Dierk
    Duda, Stephan
    Zeller, Thomas
    Krankenberg, Hans
    Ricke, Jens
    Bosiers, Marc
    Tepe, Gunnar
    Naisbitt, Scott
    Rosenfield, Kenneth
    JACC-CARDIOVASCULAR INTERVENTIONS, 2014, 7 (01) : 11 - 19
  • [49] Pushing the envelope: A drug-coated balloon for left main intervention
    Uskela, Sanna
    Knaapen, Paul
    Rissanen, Tuomas T.
    CARDIOLOGY JOURNAL, 2022, 29 (02) : 358 - 359
  • [50] Drug-coated balloon for recurrent in-stent restenosis treatment: A suitable strategy
    Piraino, Davide
    Buccheri, Dario
    Cimino, Giuliana
    Andolina, Giuseppe
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 221 : 1084 - 1086